ZYVERSA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.487 USD | -7.67% |
|
-16.44% | -50.14% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 14.26 | 4.719 | 3.408 | - | - |
| Enterprise Value (EV) 1 | 14.26 | 4.719 | 3.408 | 3.408 | 3.408 |
| P/E ratio | -1.59 x | -0.01 x | -0.3 x | -0.18 x | -0.13 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 25.9 | 524 | 759.5 | - | - |
| Reference price 2 | 549.5 | 9.000 | 4.487 | 4.487 | 4.487 |
| Announcement Date | 31/03/23 | 25/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -107.8 | -16.35 | -28.15 | -39.6 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -14.87 | -107.8 | -16.35 | -28.15 | -39.6 |
| Net income 1 | - | -106.2 | -16.35 | -28.15 | -39.6 |
| Net margin | - | - | - | - | - |
| EPS 2 | -346.5 | -1,090 | -15.05 | -25.50 | -34.85 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 31/03/23 | 25/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -2.903 | -13.93 | -2.827 | -3.845 | -4.188 | -4.6 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.903 | -13.93 | -2.827 | -3.845 | -4.188 | -4.6 |
| Net income 1 | -2.935 | -13.34 | -2.827 | -3.845 | -4.188 | -4.6 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -31.50 | -1,042 | -4.530 | -3.750 | -3.700 | -4.050 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 14/11/23 | 25/03/24 | 15/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 25/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.487
USD
Average target price
70
USD
Spread / Average Target
+1,459.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -50.14% | 3.41M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.84B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- ZVSA Stock
- Financials ZyVersa Therapeutics, Inc.
